



Curriculum vitae Europass



Informații personale

Nume / Prenume

Stanciu / Adina-Elena

Telefon(oane)

(+40) 21 227 1002

E-mail

adina.stanciu@iob.ro; adinaelenastanciu@yahoo.com

Naționalitate

Romana

Data nașterii

27.06.1969

Sex

F

Locul de muncă / Domeniul ocupațional Experiența profesională

Institutul Oncologic *Prof.Dr Al.Trestioreanu* Bucuresti / cercetator st. I – radiochimist medical pr.
Cercetare biomedicala - Sanatate

Perioada

1992 – prezent

Funcția sau postul ocupat

2019 – prezent: Sef Laborator Cancerogeneza Chimica si Biologie Moleculara – Laborator de
Cercetare cu Trasori Radioactivi
2021 – prezent: cercet.st.I, radiochimist med.pr. (Lab. Cancerogeneza Chimica si Biologie Moleculara)
2017 – 2021: cercet. st.II, radiochimist med. pr. (Lab. Cancerogeneza Chimica si Biologie Moleculara)
2008 – 2017: cercet.st.III, radiochimist med. pr. (Lab. Cancerogeneza Chimica si Biologie Moleculara)
2004 – 2008: cercet. st. III, radiochimist med. pr. (Laborator Medicina Nucleara si Terapie Izotopica)
1996 – 2004: cercet. st., radiochimist med. sp. (Laborator Medicina Nucleara si Terapie Izotopica)
1992 – 1996: asistent de cercetare (Laborator Medicina Nucleara si Terapie Izotopica)

Activități și responsabilități principale

cercetare biomedicala (coordonator proiecte de cercetare, activitate in studii clinice si experimentale)
publicarea rezultatelor in reviste de specialitate, participarea la simpozioane si congrese
participarea in calitate de conferentiar la cursuri postuniversitare de specialitate
diagnostic de laborator – imunologie clinica; radiobiologie; radioimunomarcari, radiofarmaceutice

Numele și adresa angajatorului

Institutul Oncologic *Prof.Dr.Al.Trestioreanu* Bucuresti (IOB)
Laboratorul de Cancerogeneza Chimica si Biologie Moleculara, www.iob.ro
Sos. Fundeni, Nr. 252, Sector 2, Bucuresti, RO-022328

Tipul activității sau sectorul de activitate

cercetare biomedicala, diagnostic de laborator, surse deschise de radiatii nucleare – Sanatate

Perioada

2015 – prezent

Funcția sau postul ocupat

Specialist / Expert tehnic in scheme de incercari de competenta din compartimentul laboratoarelor de
analize medicale nominalizat in OMS 1301/2007 actualizat in 2022: c) imunologie

Activități și responsabilități principale

Verificare si validare scheme de incercari de competenta (scheme de control extern al calitatii)

Numele și adresa angajatorului

Asociatia pentru Calitate in Laboratoare (CALILAB)
Str. Alex. Donici, Nr. 36, Sector 2, Bucuresti

Tipul activității sau sectorul de activitate

Sanatate

Perioada

1996 – 2002

Funcția sau postul ocupat

Asistent Universitar

Activități și responsabilități principale

Activitate didactica

Numele și adresa angajatorului

Universitatea din Bucuresti, Facultatea de Chimie

Tipul activității sau sectorul de activitate

Invatamant superior

Educatie si formare

Perioada	2021
Calificarea / diploma obtinuta	Atestat de abilitare (Dr. Habil.)
Domenii principale studiate/competente	Biologie / Conducator de doctorat
Numele si tipul institutiei de invatamant	Academia Romana (Ordinul MCID nr. 5430/07.10.2021)
Perioada	2021
Calificarea / diploma obtinuta	Cercetator stiintific gradul I
Domenii principale studiate/competente	Medicina
Numele si tipul institutiei de invatamant	Ordinul MCID nr. 818/15.12.2021
Perioada	2017
Calificarea / diploma obtinuta	Cercetator stiintific gradul II
Domenii principale studiate/competente	Medicina
Numele si tipul institutiei de invatamant	Ordinul MCID nr. 216/20.04.2017
Perioada	1995 – 2002
Calificarea / diploma obtinuta	Doctor in Chimie
Domenii principale studiate/competente	Radiochimie
Numele si tipul institutiei de invatamant	Universitatea din Bucuresti, Facultatea de Chimie
Nivelul in clasificarea internationala	ISCED 2011-8 (nivel 8 EQF/CEC)
Perioada	1987 – 1992
Calificarea / diploma obtinuta	Diploma de Licenta / Master
Domenii principale studiate/competente	Profilul: Chimie / Specializare: Radiochimie
Numele si tipul institutiei de invatamant	Universitatea Bucuresti, Facultatea de Chimie
Nivelul in clasificarea internationala	ISCED 2011-6 (nivel 6 EQF/CEC)
Perioada	2016
Calificarea / diploma obtinuta	Radiochimist medical specialist
Domenii principale studiate/competente	Imunologie Clinica
Numele si tipul institutiei de invatamant	Ministerul Sanatatii
Nivelul in clasificarea internationala	ISCED 2011-7 (nivel 7 EQF/CEC)
Perioada	2004
Calificarea / diploma obtinuta	Radiochimist medical principal
Domenii principale studiate/competente	Radiatii Nucleare
Numele si tipul institutiei de invatamant	Ministerul Sanatatii
Nivelul in clasificarea internationala	ISCED 2011-7 (nivel 7 EQF/CEC)
Perioada	1999
Calificarea / diploma obtinuta	Radiochimist medical specialist
Domenii principale studiate/competente	Radiatii Nucleare
Numele si tipul institutiei de invatamant	Ministerul Sanatatii
Nivelul in clasificarea internationala	ISCED 2011-7 (nivel 7 EQF/CEC)

Aptitudini și competențe personale

Limba materna Romana

Limbi străine cunoscute Engleza, Franceza

Autoevaluare

Nivel european (*)

Engleză

Franceză

Înțelegere		Vorbire		Sciere
Ascultare	Citire	Participare la conversație	Discurs oral	Exprimare scrisă
C1	C1	C1	C1	C1
B2	B2	A2	A2	A2

(*) [Nivelul Cadrului European Comun de Referință Pentru Limbi Străine](#)

Competențe și abilități sociale

- capacitate de a coordona realizarea de activități pentru atingerea unui obiectiv, obținută în urma coordonării proiectelor de cercetare;
- activitate didactică universitară;
- activitate didactică postuniversitară în calitate de formator acreditat de Ministerul Sănătății.

Certificări, competențe și aptitudini organizatorice

Cursuri de Management:

- 2008–2009 "Curs de formare formatori în domeniul managementului asigurării și controlului calității în laboratoarele de analize medicale", Centrul Național de Perfectionare în Domeniul Sanitar, Ministerul Sănătății, București, România (Diploma Seria F, Nr. 2342 / 22.10.2009)
- 2007 "Managementul și asigurarea calității în laboratoarele medicale", Centrul Național de Perfectionare în Domeniul Sanitar, Ministerul Sănătății, București, România

Competența managerială – proiecte științifice naționale castigate prin competiție:

Director de proiect: 3 proiecte (PN-III-P2.2.1-558PED/2020; VIASAN 372/2004; VIASAN 019/2001)
Responsabil proiect institutie partenera: 4 proiecte (PNCDI2-PCCA 90/2012; PNCDI2 42-108/2008; CEEX 146/2006; VIASAN 473/2004)

Alte competente:

2022 – prezent: Specialist European în Medicina de Laborator (EUSpLM)

Permis de exercitare a activității în domeniul nuclear – surse deschise de radiații (Nr. 200/2020)
Nivel 2 – CNCAN (2020 – 2025)

2020 – prezent: **Responsabil cu protecția radiologică** (Laborator de Cercetare cu Trasori Radioactivi)

Aptitudini organizatorice:

- 2022 – 2023: membru corespondent WG: Laboratory Medicine Credit Points, European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
- 2016 – prezent: președinte Comisia de Avizări și Acreditări a Ordinului Biochimistilor, Biologilor și Chimistilor în Sistemul Sanitar din România (OBBCSSR)
- 2009 – prezent: membru în Consiliul Național al OBBCSSR
- 2009 – prezent: membru în Comisia Profesional-Științifică, Invatamant și Legislație a OBBCSSR
- 2009 – prezent: membru în comitetul științific și organizatoric al congreselor anuale ale OBBCSSR și al cursurilor postuniversitare organizate de CALILAB (20 de manifestări științifice)
- 2015 – prezent: membru în Consiliul Științific al Asociației pentru Calitate în Laboratoare (CALILAB)
- 2020 – prezent: membru în Consiliul Științific al Institutului Oncologic "Prof. Dr. Al. Trestioreanu" București
- 2014 – prezent: membru în comisiile naționale de examen Imunologie Clinică pentru biolog, biochimist, chimist medical specialist / principal (Ministerul Sănătății)

Competențe și aptitudini tehnice

Spectrometrie de radiații gamma; spectroscopie de rezonanță electronică de spin (RES); tehnici de cinetica a reacțiilor rapide; radiocromatografie în strat subțire; radioimunomarcări; analiza proteinelor prin metode imunologice (EIA / ELISA; FIA / DELFIA / ELFA; RIA / IRMA; CLIA; ECLIA; CMIA; MEIA) etc.

Cursuri / specializări (selecție):

- 2023 2022 ESC Guidelines on Cardio-Oncology: how to implement cancer treatment monitoring in daily practice, European Society of Cardiology
- 2023 Laboratory Automation Virtual Event Series (2023), Labroots
- 2022 Prevention of radiotherapy-induced cardiovascular disease, European Society of Cardiology
- 2021 5th International BRCA Virtual Forum 2021, Singapore Medical Science
- 2020 "SIRT Workshop (Yttrium-90 Radioembolisation)", Magdeburg, Germany
- 2019 Curs CALILAB: "Managementul Calității - Medicina de Laborator Orientată către Client", Cluj
- 2019 Curs intensiv de nivel II în domeniul radioprotecției: "Protecția radiologică în domeniile SD, RDG și RDT, specialitățile: MN, TSD, AASD și RSD", organizat de AC RAD Medical Consult & Service, curs avizat de CNCAN. Certificat de absolvire Nr. 936/29.11.2019
- 2015 15th EFLM Postgraduate Course in Clinical Chemistry and Laboratory Medicine "How to assess the quality of your method?"

Competențe și aptitudini tehnice**Cursuri / specializări (selecție):**

- 2015 Advanced Lecture Course "Matrix Pathobiology, Signaling and Molecular Targets" (FEBS-MPST2015), Rhodes, Grecia
- 2014 Curs: "Lucrul cu surse deschise radiatii in radiochimie si in medicina nucleara", Centrul National de Perfectionare in Domeniul Sanitar, Ministerul Sanatatii, Bucuresti, Romania
- 2013 TDM POSDRU/81/3.2/S/58819 "Gene microarray baza si avansat", Min. Sanatatii, IOCN, Cluj
- 2013 "National Training Course on Radiopharmacy, Radiochemistry and Radioisotopes Production Site Management", IAEA TC project ROM/6/017, Magurele, Romania
- 2012 "South Eastern European Immunology School (SEEIS 2012)" – Sarajevo, Bosnia si Hercegovina
- 2012 "EQALM 2012 Symposium", Herlev, Danemarca
- 2011 Advanced Course: "Matrix Pathobiology, Signaling and Molecular Targets" (FEBS-MPST2011), Spetses, Grecia
- 2011 "EQALM 2011 Symposium", Szeged, Ungaria
- 2010 "South Eastern European Immunology School (SEEIS 2010)" – Dubrovnik, Croatia
- 2010 "EQALM 2011 Symposium", Lisabona, Portugalia
- 2009 "Investigatii Moderne in Laboratorul Medical", CALILAB, Ministerul Sanatatii, Bucuresti, Romania
- 2009 "Radioprotection – The use of open sources of ionizing radiations in medicine", Centrul National de Perfectionare in Domeniul Sanitar, Ministerul Sanatatii, Bucuresti, Romania
- 2008 "Tehnici clasice si moderne de imunologie medicala", Centrul National de Perfectionare in Domeniul Sanitar, Ministerul Sanatatii, Bucuresti, Romania
- 2008 "Fundamental Immunology Workshop - 6th edition", National Society of Immunology, Bucuresti
- 2006 6th edition of Advanced Course *From Cell and Molecular Biology at XXI Century Medicine*, Academia Romana, Institutul de Biologie si Patologie Celulara Nicolae Simionescu, Romania
- 2006 "8th Training Course on Radioactivity, Radionuclides and Radiation – A Nuclear Science Training Course with Nuclides.net", European Commission JRC, Institute for Transuranium Elements and Jozef Stefan Institute, Ljubljana, Slovenia
- 2005 "Update in management of the solid tumors", European Society for Medical Oncology (ESMO), SIOG International Symposium, Bucharest, Romania
- 2004 "New trends in diagnosis, monitoring and management of tumor disease", FESCC, Dubrovnik

Competențe și aptitudini de utilizare a calculatorului

Microsoft Office (Word, Excel, PowerPoint, Paint), aplicatii (Adobe PhotoShop si CorelDraw)

Competențe și aptitudini artistice

Pictura

Informații suplimentare**Burse internationale acordate de asociatii profesionale in urma unui proces de evaluare**

- 2017 International Travel Grant acordat de American Association for Clinical Chemistry (AACC) pentru participarea la 69th AACC Annual Meeting, San Diego, USA, unde am prezentat lucrarea "Paroxysmal, but not persistent, atrial fibrillation is associated with increased levels of transforming growth factor beta 1"
- 2013 ECOP Travel Grant acordat de ECOP project. Bursa a acoperit participarea la conferinta organizata de Regional Centre for Applied Molecular Oncology la Brno, Republica Ceha, unde am prezentat lucrarea "Differential changes in protease-antiprotease balance and serum levels of soluble tumor necrosis factor receptors during radioiodine therapy in papillary thyroid carcinomas with/without autoimmune thyroid diseases".
- 2012 International Travel Grant acordat de American Association for Clinical Chemistry (AACC) pentru participarea la 2012 AACC Annual Meeting, Los Angeles, USA, unde am prezentat lucrarea "Effects of radioiodine therapy on immune status in papillary thyroid carcinomas with/without autoimmune thyroid diseases"
- 2012 Fellowship acordat de European Federation of Immunological Societies (EFIS) pentru participarea la 4th EFIS-EJI South Eastern European Immunology School-SEEIS 2012 Sarajevo, Bosnia si Hercegovina, unde am prezentat "Effects of radioiodine therapy on protease-antiprotease balance in papillary thyroid carcinomas with/without autoimmune thyroid diseases"
- 2011 FEBS Youth Travel Fellowship (YTF) acordat de Federation of European Biochemical Societies (FEBS) pentru participarea la 3rd FEBS Advanced Lecture Course - Matrix Pathobiology, Signaling and Molecular Targets, FEBS-MPST 2011, care a avut loc in Spetses, Grecia, unde am prezentat lucrarea "Anti-inflammatory and anti-remodeling effects of cardiac resynchronization therapy in patients with chronic heart failure"

Informații suplimentare

Burse internaționale acordate de asociații profesionale în urma unui proces de evaluare

- 2011 International Travel Grant acordat de American Association for Clinical Chemistry (AACC), pentru participarea la 2011 AACC Annual Meeting, Atlanta, USA, unde am prezentat lucrarea: "Recurrence assessment in papillary thyroid carcinoma associated with autoimmune thyroid diseases, after thyroidectomy and before radioiodine therapy"
- 2011 Gallwas Grant
- 2010 Fellowship acordat de European Federation of Immunological Societies (EFIS) pentru participarea la EFIS, South Eastern European Immunology School (SEEIS 2010) – Dubrovnik, Croatia, unde am prezentat lucrarea "Effects of Cardiac Resynchronization Therapy on left ventricle remodeling"
- 2006 Gallwas Grant
- 2006 Travel Grant acordat de European Commission- Joint Research Centre pentru participarea la "8th Training Course on Radioactivity, Radionuclides and Radiation – A Nuclear Science Training Course with Nuclides.net", Institute for Transuranium Elements și Jozef Stefan Institute, Ljubljana, Slovenia
- 2004 Travel Grant acordat de Federation of European Societies of Clinical Chemistry (FESCC), pentru participarea la "The 4th FESCC Continuous Postgraduate Course in Clinical Chemistry: New Trends in Diagnosis, Monitoring and Management of Tumor Diseases", care s-a desfășurat la Dubrovnik, Croatia

Premii și distincții

- 2021 UEFISCDI: PN-III-P1-1.1-PRECISI-2021-61305 – pentru articolul: Gheorghe DC, Stanciu MM, Zamfirescu A, **Stanciu AE**. TNF- α May Exert Different Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer with/without Autoimmune Thyroiditis. Cancers. 2021;13(14):3609
- 2019 UEFISCDI: PN-III-P1-1.1-PRECISI-2019-35310 – pentru articolul: **Stanciu AE**, Popescu M, Gheorghe DC. Idiotype-specific intravenous immunoglobulin kappa free light chain deficiency. Hum Vaccin Immunother 2019;15(5):1123-1125.
- 2019 UEFISCDI: PN-III-P1-1.1-PRECISI-2019-31293 – pentru: **Stanciu AE**, Stanciu MM, Vatasescu RG. NT-proBNP and CA125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure. Cytokine 2018;111:13-19.
- 2019 Diploma Salonului de carte universitară 2019 pentru: Zamfir-Chiru-Anton A, **Stanciu AE**, Ulici A, Georgescu M, Gheorghe DC. Melatonina. Editura Universitară "Carol Davila", București
- 2018 UEFISCDI: PN-III-P1-1.1-PRECISI-2018-28383 pentru: **Stanciu AE**, Vatasescu RG, Stanciu MM, Serdarevic N, Dorobantu M. The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. Cytokine. 2018 Mar;103:63-68. doi: 10.1016/j.cyto.2017.12.026.
- 2017 UEFISCDI: PN-III-P1-1.1-PRECISI-2017-18797 pentru articolul: Koziorowski J, **Stanciu AE**, Gómez-Vallejo V, Llop J. Radiolabeled nanoparticles for cancer diagnosis and therapy. Anticancer Agents Med Chem. 2017;17(3):333-354.
- 2014 Diploma Salonului de Carte Universitară 2014 pentru: **Stanciu AE**, Carageorgheopol A, Badiu C. Markeri tumorali și endocrini. Ghid practic. Editura Universitară "Carol Davila", București, 2014
- 2011 American Association for Clinical Chemistry Academy – 2011 Distinguished Abstract Award pentru lucrarea: **Stanciu AE**, Rosu A, Tache A, Gheorghe M, Hurduc A. Recurrence assessment in papillary thyroid carcinoma associated with autoimmune thyroid diseases, after thyroidectomy and before radioiodine therapy, prezentată la 2011 AACC Annual Meeting, Atlanta, USA
- 2011 AACC Membership Grant Recipient (Gallwas Member 2011 – 2016)
- 2010 American Association for Clinical Chemistry Academy – 2010 Distinguished Abstract Award pentru lucrarea: **Stanciu AE**, Stanciu M, Vatasescu R, Iorgulescu C, Dorobantu M. Anti-inflammatory and anti-remodeling effects of Cardiac Resynchronization Therapy, prezentată la 2010 AACC Annual Meeting, Anaheim, USA
- 2006 AACC Membership Grant Recipient (Gallwas Member 2006 – 2011)
- 2004 Premiul "Eugen Mody" acordat de Asociația de Medicină de Laborator din România (AMLR) <http://amlr.ro/?p=195>
- 2003 Premiul I acordat de Societatea Română de Medicină Nucleară pentru lucrarea: Albert P, Fumarel R, Hurduc A, Stafidov N, **Stanciu AE**. "Marcarea radioactivă a metotrexatului cu izotopul Tc-99m"
- 1995 Premiul I acordat de Societatea Română de Oncologie Comparată pentru lucrarea: "Aplicații clinice ale unor markeri tumorali în cancerul glandei mamare"

Informații suplimentare

Membru in Societati Stiintifice si Asocatii Profesionale:

- European Society of Cardiology (ESC) – membru in grupurile de lucru: "Cellular Biology of the Heart" si "Cardio-Oncology"
- American Association for Clinical Chemistry (AACC) – membru in grupurile de lucru: "Clinical and Diagnostic Immunology" si "Tumor Markers and Cancer Diagnostics"
- Ordinul Biochimistilor, Biologilor si Chimistilor in Sistemul Sanitar din Romania (OBBCSSR)
- European Society for Medical Oncology (ESMO)
- European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Reviewer sau membru in colectivul editorial al unor reviste de specialitate:

Reviewer – Biomedicines, Cancers, Pharmaceuticals

Ad hoc Reviewer: Heliyon; Journal of International Medical Research; Reviews in Cardiovascular Medicine; Cureus; Frontiers in Neuroscience; Cancer Immunology, Immunotherapy; Endocrine-Related Cancer; Disease Markers; Oncology Research; Romanian Biotechnological Letters; Journal of Health Sciences etc.

Lector in cursuri postuniversitare

Markeri Tumoral. Principii generale si Ghiduri; Erori intalnite in compartimentul de imunologie; Markeri Tumoral. Ghid practic; Markeri tumoral. Recomandari privind utilizarea markerilor tumoral in practica clinica; Implicatiile acreditarii ISO 15189 si 17043 pentru imunologie; Markeri tumoral; Controlul intern al calitatii in imunologie; Biomarkers in Chronic Heart Failure; Markeri tumoral. Actualitati si perspective etc.

Lucrari stiintifice publicate: 70 (lucrari publicate in reviste cotate ISI: 43; lucrari publicate in alte reviste de specialitate: 27); 2 capitole de carte la edituri internationale; 6 carti la edituri nationale; 57 de prezentari la manifestari internationale; 79 de prezentari la manifestari nationale

Indice Hirsch: 11 (Web of Science); 13 (Google Scholar)

ORCID ID: 0000-0002-9494-6686 <https://orcid.org/0000-0002-9494-6686>

Researcher ID: U-2761-2017 <https://publons.com/researcher/1758930/adina-elena-stanciu/>
<https://www.webofscience.com/wos/author/record/951066>

Scopus Author ID: 35148508200 <https://www.scopus.com/authid/detail.uri?authorId=35148508200>

Romanian BrainMap ID: U-1700-034K-8330. <https://www.brainmap.ro/adina-elena-stanciu>

Anexe

Lista de lucrari stiintifice

Data: 08.09.2023

Semnatura



LISTA DE LUCRĂRI

CAPITOLE DE CARTE PUBLICATE LA EDITURI INTERNAȚIONALE

1. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu M, Gheorghe DC. Chapter 8: *Impact of Thyroid Disease on Heart Failure*. In the book: *Advance Heart Failure and How it Impacts the Electrophysiologists*. Dr. John Kassotis (Ed.). InTech 2017. Pages 141-157. ISBN 978-953-51-2948-6, Print ISBN: 978-953-51-2947-9. DOI: 10.5772/66283.
2. **Stanciu AE**. Chapter 15: *Synthesis and Applications of Alpha/Beta Emitter-Labelled Nanoparticles*. In: *Isotopes in Nanoparticles. Fundamentals and Applications*. Edited by Jordi Llop, Vanessa Gomez-Vallejo, Peter Neil Gibson. Pan Stanford 2016. Pages 383-427. Print ISBN: 978-981-4669-08-5, eBook: 978-981-4669-09-2, 544 pg. <https://doi.org/10.1201/b19950>

CĂRȚI PUBLICATE LA EDITURI NAȚIONALE RECUNOSCUTE CNCSIS

1. Zamfir-Chiru-Anton A, **Stanciu AE**, Ulici A, Georgescu M, Gheorghe DC. *Melatonina*. Editura Universitara "Carol Davila", Bucuresti, 2019 (144 pg), ISBN:978-606-011-071-2.
2. Contineanu M, Neacsu A, **Stanciu AE**. *Defecte de Retea*. Editura Ars Docendi, Universitatea din Bucuresti, 2017 (140 pg). ISBN 978-973-558-981-3. http://arsdocendi.ro/t_carte.php?id_carte=254
3. **Stanciu AE**, Zamfir Chiru Anton A, Gheorghe DC. *Rolul metaloproteinazelor in cancerele de cap si gat*. Editura Pro Universitaria, Colectia Medicina, Bucuresti, 2015 (138 pg), ISBN: 978-606-26-0445-5. <http://www.prouniversitaria.ro/carte/rolul-metaloproteinazelor-in-cancerle-de-cap-si-gat>
4. **Stanciu AE**, Caragheorgheopol A, Badiu C. *Markeri tumoral si endocrini. Ghid practic*. Editura Universitara "Carol Davila", Bucuresti, 2014 (156 pg), ISBN: 978-973-708-745. <https://editura.umfcd.ro/markeri-tumoral-i-endocrini/>
5. **Stanciu A**, Contineanu M, Stanciu M. *Actiunea radiatiilor ionizante asupra sistemelor biologice*. Editura Electra, Bucuresti, 2004 (193 pg), ISBN: 973-7728-26-2. <http://mail.agir.ro/carte/actiunea-radiatiilor-ionizante-asupra-sistemelor-biologice-112185.html>
6. Stanciu M, **Stanciu A**. *Senzori chimici si biochimici cu fibre optice*. Editura Electra, Bucuresti, 2003 (183 pg). ISBN: 973-8067-92-8.

LUCRĂRI ȘTIINȚIFICE PUBLICATE ÎN REVISTE INDEXATE ÎN WEB OF SCIENCE

1. **Stanciu AE**, Hurduc A, Stanciu MM, Gherghe M, Gheorghe DC, Prunoiu VM, Zamfir-Chiru-Anton A. Portrait of the Inflammatory Response to Radioiodine Therapy in Female Patients with Differentiated Thyroid Cancer with/without Type 2 Diabetes Mellitus. *Cancers (Basel)*. 2023;15(15):3793. doi: 10.3390/cancers15153793. PMID: 37568611; PMCID: PMC10417100.
2. Gheorghe DC, Enculescu A, **Stanciu AE**, Epure V, Zamfir-Chiru-Anton A. Eustachian Tube Teratoma: A Rare Entity. *Clin Pathol*. 2023;16:2632010X231195231. doi: 10.1177/2632010X231195231. PMID: 37599665; PMCID: PMC10436987.
3. Bolovan LM, Ceausu M, **Stanciu AE**, Panait ME, Busca A, Hotnog CM, Bleotu C, Gales LN, Georgescu MT, Prunoiu VM, Brasoveanu LI, Voinea SC. Correlation Studies between S100 Protein Level and Soluble MIA or Tissue MelanA and gp100 (HMB45) Expression in Cutaneous Melanoma. *J Pers Med*. 2023;13(6):898. doi: 10.3390/jpm13060898. PMID: 37373887; PMCID: PMC10305456.
4. Gherghe M, Mutuleanu MD, **Stanciu AE**, Irimescu I, Lazar AM, Toma RV, Trifanescu OG, Anghel RM. Quantitative Assessment of Treatment Response in Metastatic Breast Cancer Patients by SPECT-CT Bone Imaging-Getting Closer to PET-CT. *Cancers (Basel)*. 2023;15(3):696. PMID: 36765651; PMCID: PMC9913230 <https://doi.org/10.3390/cancers15030696>.
5. Gherghe M, Lazar AM, Mutuleanu MD, Bordea CI, Ionescu S, Mihaila RI, Petroiu C, **Stanciu AE**. Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact? *Cancers (Basel)*. 2022;15(1):207. <https://doi.org/10.3390/cancers15010207> PMID: 36612202; PMCID: PMC9818586.
6. Gheorghe DC, **Stanciu AE**, Zamfir-Chiru-Anton A, Doru O, Epure V. Moebius syndrome-Case report. *Clin Case Rep*. 2022;10(12):e6715. PMID: 36523389 <https://doi.org/10.1002/ccr3.6715>

7. Gherghe M, Lazar AM, **Stanciu AE**, Mutuleanu MD, Sterea MC, Petroiu C, Gales LN. The New Radiolabeled Peptide ^{99m}TcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs? *Cancers* 2022;14(11):2725. <https://doi.org/10.3390/cancers14112725>
8. **Stanciu AE**, Stanciu MM, Zamfirescu A, Gheorghe DC. Cardiovascular Effects of Cumulative Doses of Radioiodine in Differentiated Thyroid Cancer Patients with Type 2 Diabetes Mellitus. *Cancers* 2022;14(10):2359. <https://doi.org/10.3390/cancers14102359>
9. **Stanciu AE**, Verzia A, Stanciu MM, Zamfirescu A, Gheorghe DC. Analysis of the Correlation between the Radioactive Iodine Activity and Neutrophil-to-Lymphocyte Ratio in Patients with Differentiated Thyroid Cancer. *Cancers* 2022;14(8):1899. <https://doi.org/10.3390/cancers14081899>
10. Gherghe M, Lazar AM, Mutuleanu MD, **Stanciu AE**, Martin S. Radiomics Analysis of [¹⁸F]FDG PET/CT Thyroid Incidentalomas: How Can It Improve Patients' Clinical Management? A Systematic Review from the Literature. *Diagnostics* 2022;12(2):471. <https://doi.org/10.3390/diagnostics12020471>
11. Gherghe M, Mutuleanu M.D, **Stanciu AE**, Irimescu I, Lazar A, Bacinschi X, Anghel RM. Quantitative Analysis of SPECT-CT Data in Metastatic Breast Cancer Patients—The Clinical Significance. *Cancers* 2022;14(2):273. <https://doi.org/10.3390/cancers14020273>
12. Lete C, López-Iglesias D, García-Guzmán JJ, Leau SA, **Stanciu AE**, Marin M, Palacios-Santander JM, Lupu S, Cubillana-Aguilera L. A Sensitive Electrochemical Sensor Based on Sonogel-Carbon Material Enriched with Gold Nanoparticles for Melatonin Determination. *Sensors* 2022; 22(1):120. <https://doi.org/10.3390/s22010120>
13. Gheorghe DC, Stanciu MM, Zamfirescu A, **Stanciu AE**. TNF- α May Exert Different Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer with/without Autoimmune Thyroiditis. *Cancers* 2021;13(14):3609. doi: 10.3390/cancers13143609. PMID: 34298820.
14. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Gherghe M, Hainarosie R, Furtunescu FL, Gheorghe DC. Clinical significance of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in the first phase of burn trauma evolution. *Exp Ther Med* 2021;22(4): 1113. doi: 10.3892/etm.2021.10547.
15. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Gherghe M, Hainarosie R, Furtunescu FL and Gheorghe DC: Role and dynamics of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in burn patients. *Exp Ther Med* 2021;22(4):1062. PMID: 34434276. doi: 10.3892/etm.2021.10496.
16. Serdarevic N, Dabla P, **Stanciu AE**. Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression. *Ind J Clin Biochem* 2021;36(2):151-158. PMID: 33867705. doi: 10.1007/s12291-019-0818-6.
17. Simion L, Stanculeanu D, Capsa Cristina M, **Stanciu A**, Stefan Cristina D. Highlights from the IOB Conference on Cancer, 20-22 May 2021 and the new research vision of The Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania. *ecancer* 2021;15:ed114. <https://doi.org/10.3332/ecancer.2021.ed114>
18. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Pantea-Stoian A, Nitipir C, Gheorghe DC. Serum melatonin is inversely associated with matrix metalloproteinase-9 in oral squamous cell carcinoma. *Oncol Lett.* 2020;19(4):3011–3020.doi:10.3892/ol.2020.11392.
19. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Stoian AP, Jinga V, Nitipir C, Bucur A, Pituru TS, Arsene AL, Dragoi CM, Hainarosie R, Nicolae AC, Gherghe M, Gheorghe DC, Spandidos DA, Tsatsakis A, Papasavva M, Drakoulis N. Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma. *Oncol Lett.* 2020;19(2):1537–1543. doi: 10.3892/ol.2019.11215
20. Dan SA, Bratu OG, Marcu DR, **Stanciu AE**, Gherghiceanu F, Ionita-Radu F, Bungau S, Stanescu AMA, Mischianu D. Underactive bladder - an underestimated entity. *J Mind Med Sci.* 2020; 7(1):23–28. DOI:10.22543/7674.71.P2328.
21. **Stanciu AE**, Popescu M, Gheorghe DC. Idiotype-specific intravenous immunoglobulin kappa free light chain deficiency. *Hum Vaccin Immunother.* 2019;15(5):1123–1125. doi: 10.1080/21645515.2019.1572411. PMID: 30676854
22. **Stanciu AE**. Cytokines in heart failure. *Adv Clin Chem.* 2019;93:63–113. doi: 10.1016/bs.acc.2019.07.002. PMID:31655733.
23. Nitipir C, Neagu AM, Iaciu C, Barbu MA, Popescu BC, Orlov C, Popa AM, Constantinescu R, Pietrosanu C, Pituru S, Hainarosie R, Pantea Stoian AM, **Stanciu AE**. New biomolecules for the treatment of Disseminated Intravascular Coagulation. *Rom Biotech Lett.* 2019;24(4):580–585. doi: 10.25083/rbl/24.4/580.585.
24. Nitipir C, Barbu MA, Orlov C, **Stanciu AE**, Popa AM, Hainarosie R, Pituru S, Arsene AL, Pantea Stoian A. Type II Diabetes Mellitus - Associated Risk Factor in the Onset and Evolution of Digestive Tract Carcinoma. *Rom Biotech Lett.* 2019;24(1):140–146. doi: 10.25083/rbl/24.1/140.146. WOS:000463708100016 (IF: 0.765)
25. **Stanciu AE**, Stanciu MM, Vatasescu RG. NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure. *Cytokine.* 2018;111:13–19. doi:10.1016/j.cyto.2018.07.037.

26. **Stanciu AE**, Vatasescu RG, Stanciu MM, Serdarevic N, Dorobantu M. The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. *Cytokine*. 2018;103:63–68. doi: 10.1016/j.cyto.2017.12.026. PMID:29324263.
27. **Stanciu AE**, Sava F, Toldi G. A rare case of polyglandular autoimmune syndrome type IIIc with primary antibody failure. *Gynecol Endocrinol*. 2018;34(4):283–285. PMID: 29043872. doi: 10.1080/09513590.2017.1391775.
28. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC, Nitipir C. Serum matrix metalloproteinase-2 in head and neck squamous cell carcinoma is associated with tumor differentiation. *Rom Biotech Lett*. 2017;22(2):12419–12426.
29. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC. Imbalance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Promotes Invasion and Metastasis of Head and Neck Squamous Cell Carcinoma. *Clin Lab*. 2017;63(10):1613–1620. doi: 10.7754/Clin.Lab.2017.170339. PMID: 29035450.
30. Nitipir C, Niculae D, Orlov C, Barbu MA, Popescu B, Popa AM, Stoian Pantea AM, **Stanciu AE**, Galateanu B, Ginghina O, Papadakis GZ, Izotov BN, Spandidos DA, Tsatsakis AM, Negrei C. Update on radionuclide therapy in oncology (Review). *Oncol Lett*. 2017; 14: 7011–7015. doi: 10.3892/ol.2017.7141.
31. Koziorowski J, **Stanciu AE**, Gómez-Vallejo V, Llop J. Radiolabeled nanoparticles for cancer diagnosis and therapy. *Anticancer Agents Med Chem*. 2017;17(3):333–354. PMID: 26899184. doi: 10.2174/1871520616666160219162902.
32. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC. Serum Level of Matrix Metalloproteinase-9 in Patients with Head and Neck Squamous Cell Carcinoma. *Clin Lab*. 2016;62:1569–1574. doi:10.7754/Clin.Lab.2016.160139.
33. **Stanciu AE**, Hurduc AE, Stanciu MM. Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer. *Scand J Clin Lab Invest*. 2016; 76(8): 626–631. doi: 10.1080/00365513.2016.1230883.
34. **Stanciu AE**, Serdarevic N, Hurduc AE, Stanciu MM. IL-4, IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto's thyroiditis. *Scand J Clin Lab Invest*. 2015;75(7):539–548. doi: 10.3109/00365513.2015.1057895.
35. Neacsu A, Contineanu M, Contineanu I, **Stanciu A**. Study on the Radical Species formed by Gamma Radiolysis of Alpha Aminobutyric Acid (α AMB). *Rev Chim-Bucharest*. 2014;65(3):306–310.
36. Sandru A, Panaitescu E, Voinea S, Bolovan M, **Stanciu A**, Cinca S, Blidaru A. Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma. *J Skin Cancer*. 2014;2014:843214. doi: 10.1155/2014/843214. PMID:25045539
37. **Stanciu AE**, Vatasescu RG, Stanciu MM, Iorgulescu C, Vasile AI, Dorobantu M. Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects. *Clin Biochem*. 2013;46(3):230–234. PMID:23159290. doi: 10.1016/j.clinbiochem.2012.11.002.
38. Serdarevic N, **Stanciu AE**. Comparison of Architect i2000 for determination of Scc with IMX determination of SCC with different methods. *Clin Lab*. 2013;59(9-10):1129–1133. PMID:24273937.
39. **Stanciu AE**. Radionuclides in targeted therapy of cancer. *Rev Roum Chim*. 2012;57(1):5–13.
40. Contineanu M, Neacsu A, Contineanu I, **Stanciu AE**. Kinetics of the thermal disappearance of radicals formed during the radiolysis of ammonium paramolybdate (APMO). *Rev Roum Chim*. 2012;57(11):937–945.
41. Contineanu M, Contineanu I, Neacsu A, **Stanciu AE**. EPR study of paramagnetic centers in gamma irradiated polycrystalline ammonium paramolybdate (APMO) and ammonium parawolframate (APW). *Rev Roum Chim*. 2011;56(12):1155–1162.
42. Contineanu M, **Stanciu AE**, Neacsu A. Thermal annealing kinetics of radicals formed by the radiolysis in polycrystalline solid state of sodium wolframate. *Rev Roum Chim*. 2010;55(8):467–474.
43. **Stanciu AE**. The importance of tumor markers in oncology. *Rev Romana Med Lab*. 2008;2(11):57–61.

LUCRĂRI ȘTIINȚIFICE PUBLICATE ÎN REVISTE INDEXATE BDI ȘI ÎN ALTE REVISTE DE SPECIALITATE CU ISSN

1. Serdarevic N, **Stanciu AE**, Begic L, Uncanin S. Serum Uric Acid Concentration in Patients with Cerebrovascular Disease (Ischemic Stroke and Vascular Dementia). *Med Arch*. 2020;74(2):95-99. doi: 10.5455/medarh.2020.74.95-99
2. Neacsu A, **Stanciu AE**, Contineanu M, Gheorghe D. Effect of gamma irradiation on NaVO₃ in polycrystalline solid state. *Chem Rep*. 2020;2(1):124-131. DOI: [10.25082/CR.2020.01.002](https://doi.org/10.25082/CR.2020.01.002)
3. Gheorghe DC, Zamfir-Chiru-Anton A, Ene LE, **Stanciu AE**. Piriform sinus fistula management approach – our experience. *Ro Med J*. 2020;67(1):99-101. DOI: 10.37897/RMJ.2020.1.19

4. Gheorghe DC, Zamfir-Chiru-Anton A, Ene LE, **Stanciu AE**. Hunter syndrome revisited. Ro Med J. 2020;67(1):87-89. DOI: 10.37897/RMJ.2020.1.16
5. Gheorghe DC, Zamfir-Chiru-Anton A, Ene LE, **Stanciu AE**. Hairy polyp of the rhinopharynx – a rare and unrecognized entity. Ro J Med Pract. 2020;15(1):112-114. DOI: 10.37897/RJMP.2020.1.21
6. **Stanciu AE**, Serdarevic N, Stanciu MM, Mazilu L, Bratu O, Gherghe M, Voinea SC, Gheorghe DC. Comparative evaluation of the bladder tumor-associated antigen, urinary bladder cancer antigen, tissue polypeptide specific antigen and voided urine cytology in early detection of primary bladder tumors. Rev Chim (Bucharest). 2019;70(12):4514-4518. <https://doi.org/10.37358/RC.19.12.7786>.
7. Zamfir-Chiru-Anton A, Ulici A, **Stanciu AE**, Gheorghe DC. Atypical acute otomastoiditis - clinical case. Ro J Med Pract. Vol 13, Nr.1 (54), 2018. DOI: [10.37897/RJMP.2018.1.9](https://doi.org/10.37897/RJMP.2018.1.9)
8. Zamfir-Chiru-Anton A, **Stanciu AE**, Gheorghe DC. Cricoid malformation and endolaryngeal submucosal drilling - a possible technique. J Med Life. 2017;10(3):194-196. PMID:29075350
9. Zamfir-Chiru-Anton A, **Stanciu AE**, Gheorghe DC. Osteomyelitis of the mandible with pseudotumoral manifestation. Ro J Med Pract. 2016; vol 11; Nr.2(45): 199-202. DOI: [10.37897/RJMP.2016.2.16](https://doi.org/10.37897/RJMP.2016.2.16)
10. Zamfir-Chiru-Anton A, **Stanciu AE**, Gheorghe DC. Implications of melatonin in etiopathogenesis and treatment of autistic spectrum disorders. Rom Med J. 2016; vol. LXIII, Nr.2: 111-114. DOI: [10.37897/RMJ.2016.2.3](https://doi.org/10.37897/RMJ.2016.2.3)
11. Gheorghe DC, Ulici A, **Stanciu AE**, Zamfir-Chiru-Anton A. Bilateral external ear canal osteomas - discussion on a clinical case. J Med Life. 2016;9(4). doi: 10.22336/jml.2016.0420. PMID: 27928451
12. Contineanu M, **Stanciu AE**, Contineanu I, Neacsu A. Thermal disappearance kinetics of radicals formed during radiolysis in polycrystalline solid state of sodium wolframate dihydrate. South Braz J Chem. 2010; 18(18):49-64. doi: 10.48141/SBJCHEM.v18.n18.2010.51_2010
13. Busca A, Birtoiu A, Diaconescu A, **Stanciu A**, Stafidov N, Militaru M. Estrogen and progesterone in mammary tumors of bitch and cat / Estradiolul si progesteronul in tumorile mamare la catea si pisica. Romanian Journal of Comparative Oncology 2007; Nr.13:877-85. ISSN: 1584-6547.
14. Stanciu M, Faur D, Boev A, **Stanciu A**. ECG Measurement and Acquisition System for Heart Rate Variability Analysis. Annals of the University of Craiova – Electrical Engineering Series 2007;II(31):6–9. ISSN:1842-4805.
15. **Stanciu A**. Compararea testelor BTA si UBC cu citologia urinara spontana in diagnosticul si managementul cancerului de vezica. Revista Romana de Laborator Medical 2006; Anul I, Nr.2:32-8. ISSN 1841-866X
16. **Stanciu A**, Stanciu M. Optical Fiber Sensors in Nuclear Plants. Electrotehnica - Electronica – Automatica (EEA) 2005;53(4):15-20. ISSN: 1582–5175.
17. **Stanciu A**, Stanciu M. Influenta radiatiilor ionizante asupra organismelor vii. Electronica Aplicata. 2005; Anul VII, Nr. 37, Februarie – Martie:22–25. ISSN: 1454-2889.
18. **Stanciu AE**. Aplicatii clinice ale markerilor tumorali PSA total si PSA liber / Clinical applications of total PSA and free PSA tumor markers. Rev Romana Med Lab. 2005;1(1):33–38. ISSN: 1841-6624
19. Stanciu M, **Stanciu A**. Biosenzor cu fibre optice pentru masurarea concentratiei antigenului specific prostatic. ATEE-IEEE 2004. [indexed thorough Thomson-Reuters ISI-CPCI].
20. **Stanciu A**, Stafidov N, Stanciu M. Rolul markerilor tumorali PSA total si PSA liber in discriminarea intre hiperplazia prostatica benigna si cancerul de prostata. Revista Romana de Oncologie 2003;40(1):39–44
21. Fumarel R, Albert P, Hurduc A, Stafidov N, **Stanciu A**, Manolescu N, Moraru V, Terbea I. Marcarea radioactivă a metotrexatului cu izotopul ^{99m}Tc în vederea monitorizării scintigrafice în timp real a parametrilor chimioterapiei fotostimulate (PSCHT*). Partea a II-a. Revista Romana de Oncologie 2003;39 (1-2):97-109.
22. Fumarel R, Albert P, Stafidov N, **Stanciu A**, Hurduc A, Manolescu N, Terbea I, Moraru V, Negoita V. Marcarea radioactivă a metotrexatului cu izotopul ^{99m}Tc în vederea monitorizării scintigrafice în timp real a parametrilor chimioterapiei fotostimulate (PCHT). Partea I. Revista Romana de Oncologie 2000;37(1):62-7.
23. Contineanu M, **Stanciu A**. EPR study of radical species formed at the radiolysis of the second group selenites. Rev Chim-Bucharest. 2000;1(1-2):32–37. ISSN: 0034-7752
24. Stanciu M, Iliescu C, Pantelimon B, **Stanciu A**. Modelarea si simularea functionarii senzorilor de pH cu fibre optice. Metrologie. 1998; XIV(1):14–18. ISSN: 1220-546X.
25. Contineanu M, **Stanciu A**. Kinetics and mechanism of thermal annealing of the paramagnetic centres in γ irradiated BaCrO₄. Analele Universitatii Bucuresti: Chimie 1996; Anul V (serie noua): 43–49. ISSN: 1220-871X
26. Contineanu M, **Stanciu A**. Cinetica dispariției termice a speciilor radicalice formate la radioliza cromatilor din grupa a II-a. Rev Chim-Bucharest. 1996;47(2):139–142. ISSN: 0034-7752
27. Contineanu M, **Stanciu A**. ESR - Study of radical species formed at the radiolysis of the second group chromates. Analele Universitatii Bucuresti: Chimie 1995; Anul IV (serie noua): 45–52. ISSN: 1220-871X

BREVETE DE INVENTIE

1. **Brevet de Inventie nr. 132002/28.02.2023**, INVENTATORI: Diaconu CC, Matei L, Dragu LD, Bleotu C, Chivu-Economescu M, Aldea-Pitica IM, Necula LG, Mambet C, Neagu AI, Botezatu A, Popescu I, Dima S, Nastase A, Tica V, Ilie V, Florea R, Sorop A, Bacalbasa N, Cucu D, Ivan L, Antohe F, Boteanu R, Uyy E, Suica V, **Stanciu A**, Negoita V, Gruia MI, Anghel R, Cinca S. "Metoda de stabilire a chemogramei personalizate utilizată în managementul pacientului cu cancer pancreatic".

STUDII CLINICE

1. **Studiu Clinic nr. 18129/24.09.2020** (Institutul Oncologic "Prof.Dr.Al.Trestioreanu" București) - *Cardiotoxicitatea asociată terapiei antineoplazice; evaluare prin imagistica radionuclidică și biomarkeri moleculari*. Cercetatori principali: Dr. Adina-Elena Stanciu și Dr. Mirela Gherghe
2. **Studiu Clinic nr. 6627/04.10.2017** (Spitalul Clinic de Urgență Chirurgie Plastică, Reparatrice și Arsuri) - *Remodelarea matricii extracelulare la pacientul ars*. Cercetatori principali: Dr. Adina Zamfir-Chiru-Anton, Dr. Adina-Elena Stanciu, Dr. Dan Cristian Gheorghe
3. **Studiu Clinic Nr. 12461/18.07.2014** (Institutul Oncologic "Prof.Dr. Al.Trestioreanu" București și Institutul pentru Ocrotirea Mamei și Copilului "Alfred Rusescu") - *Testări specifice de citometrie în flux pentru pacienți cu imunodeficiență primară*. Cercetatori principali: Dr. Adina-Elena Stanciu și Dr. Alexis Cochino

DIRECTOR / RESPONSABIL DE PROIECT (Proiecte câștigate prin competiție)

1. **Director de proiect (CO):** *Diagnosticul precoce și predicția cardiotoxicității indusă de terapia cu iod radioactiv la pacienți cu cancer tiroidian diferențiat: de la imagistica cardiacă la biomarkeri inovatori*, acronim THYCCARAI, PN-III-P2-2.1-558PED/2020, UEFISCDI, **2020 – 2022**.
2. **Responsabil de proiect instituție parteneră (P5):** *Rolul S100A4 și MAP4K4 în progresia adenocarcinomului pancreatic ductal*, acronim S100MAP, PNCDI2-PCCA 90/2012, UEFISCDI. Parteneri: (1) Institutul Clinic Fundeni; (2) SC RNTECH SRL; (3) Institutul de Biologie și Patologie Celulară "N. Simionescu"; (4) Institutul de Virusologie "Ștefan S. Nicolau"; (5) Institutul Oncologic "Prof.Dr.Al.Trestioreanu" București. Director de proiect: Prof. Dr. Irinel Popescu, **2012 – 2016**
3. **Responsabil de proiect instituție parteneră (P2):** *Markeri periprocedurali de succes ai terapiei ablativă la pacienții cu fibrilație atrială paroxistică / persistentă recurentă*, acronim CARDIOMAP, PNCDI2 42-108/2008, UEFISCDI. Parteneri: (1) Spitalul Clinic de Urgență București; (2) Institutul Oncologic „Prof.Dr.Al.Trestioreanu” București; (3) Universitatea Politehnică din București; (4) SC Wing Computer Group SRL. Director de proiect: Prof. Dr. Maria Dorobanțu, **2008 – 2011**
4. **Responsabil de proiect instituție parteneră (P3):** *Evaluarea multimarker a răspunsului la terapia de resincronizare cardiacă la pacienții cu insuficiență cardiacă cronică*, acronim CARDIOSYNC, CEEEX 146/2006. Parteneri: (1) Spitalul Clinic de Urgență București; (2) Institutul de Boli Cardiovasculare Timisoara; (3) Institutul Oncologic „Prof.Dr.Al.Trestioreanu” București; (4) Universitatea "Politehnică" din București; (5) SC Wing Computer Group SRL. Director de proiect: Prof. Dr. Maria Dorobanțu, **2006 – 2009**
5. **Director de proiect (CO):** *Monitorizarea cancerelor vezicale superficiale. Corelații între markerii tumorali (de masă și de activitate), citologie urinară (spontană și exfoliată) și cistoscopie*, VIASAN 372/2004. Parteneri: (1) Institutul Oncologic „Prof.Dr.Al.Trestioreanu” București; (2) Universitatea de Medicină și Farmacie "Carol Davila"; (3) Universitatea "Politehnică" din București. **2004 – 2006**.
6. **Responsabil de proiect instituție parteneră (P2):** *Studiul obținerii modelului trusei de dozare imunoradiometrică a Antigenului Carcinoembrionic (CEA) - marker tumoral important în managementul cancerului*, VIASAN 473/2004. Parteneri: (1) Institutul Național de Cercetare-Dezvoltare pentru Fizică și Inginerie Nucleară "Horia Hulubei"; (2) Institutul Oncologic "Prof.Dr. Al.Trestioreanu" București. Director de proiect: Dr. Virginia Borza, **2004 – 2006**.
7. **Director de proiect (CO):** *Studiul corelației dintre PSA total și PSA liber în diagnosticarea și monitorizarea cancerului de prostată*, VIASAN 019/2001, **2001 – 2003**

COMUNICĂRI ȘTIINȚIFICE LA CONFERINȚE INTERNAȚIONALE

1. **Stanciu AE**, Bolovan LM, Stanciu MM, Zamfirescu A. Handling of serial blood samples collected from differentiated thyroid cancer patients undergoing radioiodine therapy. WorldLab-EuroMedLab Roma 2023 – Rome, Italy, May 21-25, 2023. DOI 10.1515/cclm-2023-7058. Clin Chem Lab Med 2023; 61, Special Suppl, P1772, pp S1856, May 2023 (e-Poster)
2. **Stanciu AE**, Bolovan LM, Stanciu MM, Gherghe M. Radioactive iodine therapy induces tissue inhibitor of metalloproteinase-1 expression. WorldLab-EuroMedLab Roma 2023 – Rome, Italy, May 21-25, 2023. DOI 10.1515/cclm-2023-7039. Clin Chem Lab Med 2023; 61, Special Suppl, P0322, pp. S408, May 2023 (e-Poster)
3. **Stanciu AE**, Bolovan LM, Stanciu MM, Zamfirescu A. The interplay of peripheral circulating free DNA and platelet-to-lymphocyte ratio in patients with differentiated thyroid cancer with/without type 2 diabetes mellitus undergoing radioiodine therapy. ESMO Congress 2022, Paris 09-13.09.2022, France. Annals of Oncology 2022;33(suppl 7): S1296-S1297, DOI:[10.1016/j.annonc.2022.07.1730](https://doi.org/10.1016/j.annonc.2022.07.1730)
[https://www.annalsofoncology.org/article/S0923-7534\(22\)03581-5/fulltext](https://www.annalsofoncology.org/article/S0923-7534(22)03581-5/fulltext).
4. **Stanciu AE**, Bolovan LM, Lazar AM, Mutuleanu MD, Stanciu MM, Gales L, Zamfirescu A, Gherghe M. Growth/differentiation factor-15 from biomarker to target in cancer. Molecular Analysis for Precision Oncology Congress 2022 (MAP 2022), Amsterdam 14-16.10.2022, Netherlands. Annals of Oncology 2022; 33(suppl 8): S1383-S1430. DOI: <https://doi.org/10.1016/j.annonc.2022.09.038>
5. **Stanciu AE**, Bolovan M, Zamfirescu A, Stanciu MM, Panait ME. Mechanistic insights into the role of B cells in radioiodine therapy of differentiated thyroid cancer associated with type 2 diabetes mellitus. Immunotherapy Bridge and Melanoma Bridge 2021. 01-02.12.2021 (Oral Communication). J Transl Med 2022; 20(1):6. <https://doi.org/10.1186/s12967-022-03290-1>
6. **Stanciu AE**, Bolovan M, Zamfirescu A, Stanciu MM, Panait ME. TGF- β 1: A crucial mediator of radioiodine therapy induced anti-tumor immunity. Molecular Analysis for Precision Oncology Virtual Congress 2021. 07-09.10.2021. Annals of Oncology 2021; 32(56): S1365-S1366 <https://doi.org/10.1016/j.annonc.2021.08.2062>
7. **Stanciu AE**, Bolovan M, Frasineanu C, Stanciu MM, Verzia A, Zamfirescu A. Effects of high cumulative radioiodine dosage on cardiovascular disease in differentiated thyroid cancer patients with/without type 2 diabetes mellitus. Excellence in Oncology Care (EIOC) 2021. 21-23.10.2021. Dubai, UAE
8. **Stanciu AE**, Hurduc AE, Stanciu MM, Bolovan M, Zamfirescu A. TGF- β 1 and TNF- α : Antagonistic cytokines controlling extracellular matrix remodeling after radioactive iodine therapy for papillary thyroid carcinoma. Molecular Analysis for Precision Oncology Virtual Congress 2020. 9-10.10.2020. Annals of Oncology 2020; 31: S1229. DOI: <https://doi.org/10.1016/j.annonc.2020.08.2198>
9. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Gheorghe DC. Reduction in serum melatonin level may promote head and neck squamous cell carcinoma invasion and metastasis via targeting matrix metalloproteinase-9. EuroMedLab 2019, 19-23 May, Barcelona, Spain. Clin Chim Acta 2019; 493 (Supplement1): S126-S127. <https://doi.org/10.1016/j.cca.2019.03.269>
10. **Stanciu AE**, Popescu M. Intravenous immunoglobulin as an idiotype vaccine? EuroMedLab 2019, 19-23 May, Barcelona, Spain. Clin Chim Acta 2019; 493 (Supplement1): S237. <https://doi.org/10.1016/j.cca.2019.03.490>
11. Bolovan M, Busca A, **Stanciu A**, Panait M, Sandru A, Voinea S, Cinca S. Immunoassay techniques for specific skin cancer biomarkers. European Biotechnology Congress 2019, April 11-13, Valencia, Spain. J Biotechnol 2019; 305(Supplement): S78. <https://doi.org/10.1016/j.jbiotec.2019.05.271>
12. **Stanciu AE**, Hurduc AE, Zamfirescu A, Stanciu MM. TGF- β and TNF- α : antagonistic cytokines controlling extracellular matrix remodeling after radioactive iodine therapy for papillary thyroid carcinoma. Excellence in Oncology Care Congress, 17-19.11.2019, Dubai, UAE.
13. Bolovan M, Cinca S, Busca A, **Stanciu AE**, Panaitescu E, Sandru A, Voinea S. Identifying the melanoma patients with high risk for metastasis. European Biotechnology Congress 2018, April 26-28, Athens, Greece. J Biotechnol 2018; 280: S74. DOI: 10.1016/j.jbiotec.2018.06.242
14. **Stanciu AE**, Sava F, Toldi G. A new case of polyglandular autoimmune syndrome type IIIC with primary antibody failure. 3rd International Primary Immunodeficiencies Congress, 08-10.11.2017, Dubai, UAE.
15. **Stanciu AE**, Panait ME, Hurduc AE, Zamfirescu A, Stanciu MM, Cinca S. Transforming growth factor-beta 1 is a major mediator of radioactive iodine therapy-induced anti-tumor immunity. 42nd FEBS Congress, 10-14.09.2017, Jerusalem, Israel. FEBS J 2017 284 (Suppl 1): 280-280. DOI: 10.1111/febs.14174.
16. **Stanciu AE**, Vatasescu RG, Iorgulescu C, Stanciu MM, Dorobantu M. Elevated CA-125 levels are associated with increased immune activation in coronary sinus blood samples of patients with chronic heart failure. 69th AACC Annual Meeting, 30.07-03.08.2017, San Diego, CA, USA. Clin Chem 2017;63(S10): S26-S26.

17. **Stanciu AE**, Vatasescu RG, Stanciu MM, Dorobantu M. Paroxysmal, but not persistent, atrial fibrillation is associated with increased levels of transforming growth factor beta1. 69th AACC Annual Meeting, 30.07-03.08.2017, San Diego, CA, USA. Clin Chem 2017;63(S10): S96-S96.
18. Bolovan M, Voinea S, Panaitescu E, **Stanciu A**, Busca A, Cinca S, Sandru A. Concomitant determination of MIA and S100 proteins as prognostic factors in cutaneous malignant melanoma. European Biotechnology Congress, 25-27.05.2017, Dubrovnik, Croatia. J Biotechnol 2017;256 (Suppl): S78-S78. DOI: 10.1016/j.jbiotec.2017.06.1066.
19. **Stanciu AE**, Hurdac AE, Zamfirescu A, Stanciu MM. Predictive value of tissue inhibitor of metalloproteinases-1 in response to radioiodine therapy. The 41st FEBS Congress, Sept. 03-08, 2016, Kusadasi, Turkey. The FEBS Journal 2016; 283 (Suppl. 1): 429-440 DOI: 10.1111/febs.13903. P-02.07.5-004.
20. **Stanciu AE**, Hurdac AE, Zamfirescu A, Stanciu MM. Radioiodine therapy induces tissue inhibitor of metalloproteinase-1 expression. UAE Cancer Congress 2016, Oct. 20-22, Dubai, Book of Proceedings, 2016.
21. **Stanciu AE**, Panait ME, Hurdac AE, Stanciu MM. Transforming growth factor-beta 1 is a major mediator of tissue responses to radioactive iodine therapy. 5th FEBS Advanced Lecture Course - Matrix Pathobiology, Signaling and Molecular Targets, FEBS-MPST 2015, Sept. 24-29, Rhodes, Book of Proceedings, P71, pp.129. Available from: <http://www.febs-mpst2015.upatras.gr/attachments/article/88/FEBS%202015.pdf>
22. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S. Utility of simultaneous measurement of three serum tumor markers in melanoma patients. Melanoma and Immunotherapy Bridge 2015, Dec 1-4, Naples, Italy. J Transl Med 14(S1) · July 2016. DOI: 10.1186/s12967-016-0791-2.
23. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S. The significance of various cut-off levels of Melanoma Inhibitory Activity in evaluation of cutaneous melanoma patients. Melanoma and Immunotherapy Bridge 2015, Dec 1-4, Naples, Italy. J Transl Med 14(S1) · July 2016. DOI: 10.1186/s12967-016-0791-2.
24. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S, Blidaru A. Melanoma Inhibitory Activity protein in malignant melanoma: is it useful? 12th EADV Spring Symposium, March 5-8, Valencia, 2015, Book of Proceedings, P036 e-Poster.
25. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S, Blidaru A. Simultaneous determination of two serum tumor markers in assessing malignant melanoma patients. Melanoma Bridge 2014, Dec 3-6, Naples, Italy. J Transl Med 2015, 13(Suppl 1):P9. doi:10.1186/1479-5876-13-S1-P9. PMCID: PMC4315289.
26. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S, Blidaru A. Clinical value of Melanoma Inhibitory Activity in stratifying malignant melanoma patients. Melanoma Bridge 2014, Dec 3-6, Naples, Italy. J Transl Med 2015, 13(Suppl 1):P10. doi:10.1186/1479-5876-13-S1-P10. PMCID: PMC4315275.
27. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S, Blidaru A. Melanoma Inhibitory Activity and regional lymph node status in malignant melanoma patients. Melanoma Bridge 2014, Dec 3-6, Naples, Italy. J Transl Med 2015, 13(Suppl 1):P11. doi:10.1186/1479-5876-13-S1-P11. PMCID: PMC4315276.
28. **Stanciu AE**, Hurdac AE, Stanciu MM. Impact of short-term hypothyroidism after levothyroxine-withdrawal on N-Terminal pro-A-type and N-Terminal pro-B-type natriuretic peptides in patients with differentiated thyroid carcinoma. IFCC WorldLab Istanbul 2014, 22-26.06.2014, Istanbul, Turkey. Clin Chem Lab Med 2014, 52, Special Suppl, pp S783. DOI: 10.1515/cclm-2014-4022.
29. **Stanciu AE**, Hurdac AE, Sasareanu A, Stanciu MM. Differential changes in protease-antiprotease balance and serum levels of soluble tumor necrosis factor receptors during radioiodine therapy. 38th FEBS Congress, 06-11.07.2013, Saint Petersburg, Russia. FEBS Journal Supplement 2013, 280:PSW04.S16-194, pp. 338.
30. **Stanciu AE**, Sasareanu A, Hurdac A. Effects of radioiodine therapy on protease-antiprotease balance and serum levels of soluble tumor necrosis factor receptors in papillary thyroid carcinomas with/ without autoimmune thyroid diseases. 4th FEBS Advanced Lecture Course - Matrix Pathobiology, Signaling and Molecular Targets, FEBS-MPST 2013, Sept 26-Oct1, Kos, Book of Proceedings, P36, pp.103. Available from: <http://www.febs-mpst2013.upatras.gr/attachments/article/13/FEBS%202013.pdf>
31. **Stanciu A**, Sasareanu A, Hurdac A. Differential changes in protease-antiprotease balance and serum levels of soluble tumor necrosis factor receptors during radioiodine therapy in papillary thyroid carcinomas with/without autoimmune thyroid diseases. Scientific Writing Workshop: Workshop on Writing Research Articles and Proposals in Cancer Research. Oct 24-25, 2013, Brno. <http://www.recamo.cz/cz/akce/scientific-writing-workshop/>
32. **Stanciu AE**, Sasareanu A, Hurdac A. Effects of radioiodine therapy on extracellular matrix degradation in papillary thyroid carcinomas with/without autoimmune thyroid diseases. 22nd IUBMB and 37th FEBS Congress. 04-09.09.2012, Sevilla, Spain. FEBS Journal 2012, 279 (Suppl.1), P04-61, pp.104.
33. **Stanciu AE**, Sasareanu A, Hurdac A. Effects of radioiodine therapy on protease-antiprotease balance in papillary thyroid carcinomas with/without autoimmune thyroid diseases. 4th EFIS-EJI South Eastern European Immunology School - SEEIS 2012, Sept 20-23, Sarajevo, Book of Proceedings, pp.14.
34. **Stanciu AE**, Sasareanu A, Hurdac A, Zamfirescu A. Effects of radioiodine therapy on imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in papillary thyroid

- carcinomas with/without autoimmune thyroid diseases. 2012 AACC Annual Meeting, 15.07-19.07.2012, Los Angeles, CA, USA. Clin Chem 2012, 58(10), Supplement, C-118, pp.A124.
35. Stanciu AE, Panait M, Sasareanu A, Hurdud A, Zamfirescu A. Effects of radioiodine therapy on immune status in papillary thyroid carcinomas with/without autoimmune thyroid diseases. 2012 AACC Annual Meeting, 15.07-19.07.2012, Los Angeles, CA, USA. Clin Chem 2012, 58(10), Supplement, C-117, pp.A124.
 36. **Stanciu AE**, Vatasescu R, Stanciu M, Dorobantu M. Immediate effects of radiofrequency catheter ablation for paroxysmal/persistent atrial fibrillation. 2012 AACC Annual Meeting, 15.07-19.07.2012, Los Angeles, CA, USA. Clin Chem 2012, 58(10), Supplement, A-01, pp.A2.
 37. **Stanciu AE**, Vatasescu R, Iorgulescu C, Stanciu M, Dorobantu M. Immediate effects of cardiac resynchronization therapy on N-terminal pro-brain natriuretic peptide and systemic inflammation. ESC Congress 2011, 27-31.08.2011, Paris, France. Eur Heart J 2011, 32, 40-40, P474 in e-Library.
 38. **Stanciu AE**, Vatasescu R, Iorgulescu C, Stanciu M, Dorobantu M. Immediate effects of cardiac resynchronization therapy. 2011 AACC Annual Meeting, 24-28.07.2011, Atlanta, GA, USA. Clin Chem 2011, 57(10), Supplement, C-12, pp. A99.
 39. **Stanciu AE**, Gluck G, Neagoe L, Stanciu M, Sinescu I. Remodeling of extracellular matrix in early recurrence of superficial bladder cancer. 2011 AACC Annual Meeting, 24-28.07.2011, Atlanta, GA, USA. Clin Chem 2011, 57(10), Supplement, A-32, pp. A11.
 40. **Stanciu AE**, Rosu A, Tache A, Gherghhe M, Hurdud A. Recurrence assessment in papillary thyroid carcinoma associated with autoimmune thyroid diseases, after thyroidectomy and before radioiodine therapy. 2011 AACC Annual Meeting, 24-28.07.2011, Atlanta, GA, USA. Clin Chem 2011, 57(10), Supplement, E-109, pp. A207.
 41. **Stanciu A**, Vatasescu R, Iorgulescu C, Stanciu M, Dorobantu M. Anti-inflammatory and anti-remodeling effects of cardiac resynchronization therapy in patients with chronic heart failure. 3rd FEBS Advanced Lecture Course - Matrix Pathobiology, Signaling and Molecular Targets, FEBS-MPST 2011, Sept 2-7, Spetses, Book of Proceedings, P32, pp.99. http://www.febsmpst2011.upatras.gr/attachments/article/83/PROCEEDINGS_FEBS-MPST_2011.pdf
 42. **Stanciu AE**, Stanciu M, Vatasescu R, Iorgulescu C, Dorobantu M. Anti-inflammatory and anti-remodeling effects of Cardiac Resynchronization Therapy. 2010 AACC Annual Meeting, 25-29.07.2010, Anaheim, CA, USA. Clin Chem 2010; 56(6), Supplement, C-86, pp. A133.
 43. **Stanciu AE**, Stafidov N, Hurdud A, Fumarel R, Cinca S. Serum cytokines profiling in well differentiated thyroid Carcinoma. 2010 AACC Annual Meeting, 25-29.07.2010, Anaheim, CA, USA. Clin Chem 2010, 56(6), Supplement, D-178, pp. A208.
 44. Ionescu L, **Stanciu AE**, Trifanescu R. Pattern of cytokines in Graves' disease after treatment with methimazol. 2010 AACC Annual Meeting, 25-29.07.2010, Anaheim, CA, USA. Clin Chem 2010, 56(6), Supplement, B-49, pp. A68.
 45. **Stanciu A**, Stanciu M, Vatasescu R, Iorgulescu C, Dorobantu M. Effects of Cardiac Resynchronization Therapy on left ventricle remodeling. Prezentare orala invitata. EFIS-EJI South Eastern European Immunology School - SEEIS 2010, Oct 2-4, Dubrovnik, Book of Proceedings, pp.17. <http://www.bnitm.de/seeis2010/Programme/SEEIS2010%20final.pdf>
 46. **Stanciu AE**, Dorobantu M, Vatasescu R, Iorgulescu C, Stanciu M. Inflammatory Markers Remodeling after Cardiac Resynchronization Therapy. 2009 AACC Annual Meeting, 19-23.07.2009, Chicago, IL, USA. Clin Chem 2009, 55(6), Supplement, p. A-68.
 47. **Stanciu AE**, Stafidov N, Gluck G, Sinescu I, Neagoe L, Stanciu M. A Comparison of Some Urine Biomarkers to Cytology and Cystoscopy in Patients with Recurrent Bladder Tumors. 2009 AACC Annual Meeting, 19-23.07.2009, Chicago, IL, USA. Clin Chem 2009, 55(6), Supplement, p. A-116.
 48. **Stanciu AE**, Dorobantu M, Vatasescu R, Iorgulescu C, Stanciu M. Inflammatory markers in patients with heart failure. EUROMEDLAB 2009, 07-11.06.2009, Innsbruck, Austria. Clin Chem Lab Med 2009, 47, Special Supplement, pp.135.
 49. **Stanciu AE**, Stafidov N, Bogdan M, Gluck G, Sinescu I, Neagoe L, Stanciu M. Clinical evaluation of some urine markers and comparison to urinary cytology and cystoscopy in patients with recurrent bladder tumors. EUROMEDLAB 2009, 07-11.06.2009, Innsbruck, Austria. Clin Chem Lab Med 2009, 47, Special Supplement, pp.135.
 50. OT Greco, A Berruezo, P Castellant, RG Vatasescu, FZ Khan, A Meiltz, A Mihalcz, RJ Van Bommel, S Sideris, A Laish-Farkash, WPM Van Meerwijk, S Partemi, P Saravanan, FJ Lacunza Ruiz, G De Roest, AC Abreu, L Mont, D Tamborero, M Sitges, D Andreu, E Silva, J Brugada, E Orhan, M Fatemi, Y Etienne, V Valls-Bertault, JJ Blanc, C Iorgulaescu, A Vasile, D Constantinescu, **A Stanciu**, N Dumitrescu, M Dorobantu, PA Read, MS Virdee, CS Foldesi, M Nobuyoshi. The Predictors of Ventricular Arrhythmic Events after Cardiac Resynchronization Therapy. Europace 2009,11(2),NP-NP. DOI: <http://dx.doi.org/10.1093/europace/euq241>.

51. **Stanciu AE**, Stafidov N, Salageanu A, Dorobantu M, Vatasescu R, Stanciu M. Inflammatory Markers Involved in Patients Undergoing Cardiac Resynchronization Therapy. 2008 AACC Annual Meeting, 27-31.07.2008, Washington, DC, USA. Clin Chem 2008, 54(6), B-138, pp. 93.
52. Anghel R, Gruia I, Oprea L, Minea L, Bacinschi X, **Stanciu AE**. The monitoring of the apoptosis induction after boron neutron capture therapy in experimental hepatoma. 19th International Congress of Anti-Cancer Treatment, Paris, France, Feb 5-8, 2008. Proceedings of the ICACT 2008.
53. **Stanciu AE**, Stafidov N, Stanciu M. Biomarkers used in monitoring of patients with chronic heart failure. Rev Romana Med Lab 2007, vol.7, Nr.2, CB2, pp.19-20.
54. Glück G, Sinescu I, Stoica R, Dragoescu O, **Stanciu AE**, Stafidov N, Bogdan M, Stanciu M. BTA, UBC, TPS tumor markers, urinary cytology and cystoscopy in recurrent bladder tumors. Urology 2007;70(3) Supplement: 237. DOI: <http://dx.doi.org/10.1016/j.urology.2007.06.758>.
55. Glück G, Sinescu I, Stoica R, Dragoescu O, **Stanciu AE**, Stafidov N, Bogdan M, Stanciu M. BTA, UBC, TPS tumor markers, urinary cytology and cystoscopy bladder tumors. Urology 2006, 105 (1).
56. **Stanciu AE**, Stafidov N, Hurduc A, Albert P, Fumarel R. Biochemical markers (TSH, ANTI-TG, TG) complementarity with scynthigraphic exam in metabolic radiotherapy of thyroid cancer. Rev Romana Med Lab 2006, vol. 3, Nr.2, P15, pp.85-86.
57. **Stanciu AE**, Stafidov N, Bogdan M, Gluck G, Sinescu I, Stoica R, Dragoescu O, Stanciu M. Clinical evaluation of a few tumor markers (BTA Trak, UBC, TPS) and comparison to citology and cystoscopy in patients with recurrent bladder tumors. Rev Romana Med Lab 2006, vol.3, Nr.2, P16, pp.87-88.

COMUNICĂRI ȘTIINȚIFICE LA MANIFESTĂRI NAȚIONALE

1. **Stanciu AE**, Bolovan M, Verzia A, Zamfirescu A. Molecular radiotherapy requires the evaluation of radioactivity in biological samples collected from cancer patients treated with different radiopharmaceuticals. Conferinta Zilele Medicale si Stiintifice ale IOB. 04-07 Mai 2023
2. Bolovan ML, Gales LN, **Stanciu AE**, Busca A, Panait ME, Brasoveanu LI. Dynamic variation of the T lymphocyte's subsets, B lymphocytes and NK cells during nivolumab therapy in cutaneous melanoma patients. Conferinta Zilele Medicale si Stiintifice ale IOB. 04-07 Mai 2023
3. **Stanciu AE**. Prediction models of lung cancer based on tumor markers. Lung Cancer Regional Conference. 03-04.09.2021
4. **Stanciu AE**, Bolovan LM, Frasineanu C, Stanciu MM, Verzia A, Tegus T, Nicorovici C, Dumitrescu A, Zamfirescu A. Cardiovascular risk assessment in patients with differentiated thyroid cancer undergoing radioiodine therapy. IOB Medical and Scientific Days. "The role of the tumor board in personalized medicine". 20-22.05.2021. Oncolog-Hematolog, Anul XV, 55(2), 2021. DOI: 10.26416/OnHe.55.2.2021
5. Kajanto L, Gherghe M, **Stanciu AE**, Stanculeanu D. Cancer therapy-induced cardiotoxicity: assessment by radionuclide imaging and molecular biomarkers. National Congress of Oncology. 03-04.09.2021. Poiana Brasov, Romania
6. **Stanciu AE**, Hurduc AE, Bolovan M, Stanciu M, Mihai M, Stoica R, Sinescu I. Diagnostic performance of a multi-biomarker panel for the non-invasive detection of bladder cancer. "Interdisciplinary Perspectives in Oncology" Conference. 27-29.09.2020
7. **Stanciu AE**, Stanciu MM, Gluck Gabriel, Sinescu I. Diagnostic performance of a multi-biomarker panel in bladder cancer. The 16th Conference of OBBCSSR, Bucharest, 10 November 2020
8. **Stanciu AE**, Stanciu MM, Gluck G, Sinescu I. Identification, using ROC curves, of the best combination of biomarkers for the primary assessment of bladder cancer. The 15th Conference of OBBCSSR, Bucharest, 9 November 2019.
9. **Stanciu AE**, Lazar VE, Alecsa GN, Sasareanu AM. The beneficial effects of Hyperbaric Oxygen Therapy from the point of view of laboratory medical analysis. The 15th Conference of OBBCSSR, Bucharest, 9 Nov. 2019.
10. **Stanciu AE**. Could too much "good" HDL cholesterol be bad? The 14th Conference of OBBCSSR, Bucharest, 10 November 2018.
11. **Stanciu AE**, Stanciu MM, Vatasescu RG. The concentration of CA 125 in serum from the coronary sinus reflects the severity of heart failure. The 14th Conference of OBBCSSR, Bucharest, 10 November 2018.
12. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC. Imbalance between matrix metalloproteinases and their tissue inhibitors is associated with metastatic spread via lymphatic pathways in head and neck squamous cell carcinomas. Institute of Oncology Conference. 17-19 May 2018. Oncolog-Hematolog.ro, XII. No.43 (2/2018), pp 31. DOI: 10.26416/OnHe.43.2.2018

13. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC. Imbalance between matrix metalloproteinases and their tissue inhibitors in head and neck squamous cell carcinoma. Institute of Oncology Conference. 15-17 May 2017. Oncolog-Hematolog.ro, XI. No.39 (2/2017), pp 31
14. **Stanciu AE**. Errors in immunology department of medical analysis laboratory. The 13th National Conference of OBBCSSR. 12 November 2016, Bucharest.
15. **Stanciu AE**, Negoita V, Gruia MI, Bleotu C, Diaconu C, Botezatu A, Tica V, Ilie V, Florea R, Sorop A, Dima S, Popescu I. Alginate-encapsulated human pancreatic cancer cells for development of mouse models. Workshop "New methodologies and advanced nanomaterials for electrochemical biosensors". Faculty of Applied Chemistry and Materials Science. University Politehnica of Bucharest, 20 May 2016, Bucharest. <http://www.microbiosens.ro/index.php/workshop>
16. Bolovan M, Sandru S, Voinea S, **Stanciu A**, Busca A, Cinca S. Significance of MIA and S100 proteins in the evaluation of patients with cutaneous malignant melanoma. Conference of the Romanian Society for Radiotherapy and Medical Days of Institute of the Oncology, Bucharest, November 05-07, 2015, Book of Proceedings, P2, pp.83.
17. **Stanciu AE**, Sasareanu A, Hurdud A, Albert Paul. Immune status assessment in patients with papillary thyroid carcinoma associated with autoimmune thyroid diseases, after thyroidectomy and before radioiodine therapy. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology, Bucharest, November 17-19, 2011
18. **Stanciu AE**, Panait M, Sasareanu A, Hurdud A, Zamfirescu A, Albert P, Tegus T, Vaduva M, Nicorovici C, Dragomir D. Effect of radioiodine therapy on immune status of patients with papillary thyroid carcinoma with/without autoimmune thyroid disease. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology, Bucharest, November 17-19, 2011
19. **Stanciu AE**, Stanciu M, Vatasescu R, Iorgulescu C, Dorobantu M. Effects of resynchronization therapy. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology, Bucharest, November 18-20, 2010
20. **Stanciu AE**, Ionescu L, Trifanescu R. The immune status in Graves' disease and papillary thyroid cancer. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology, Bucharest, November 18-20, 2010
21. **Stanciu AE**. External quality assessment programmes for medical analysis laboratories. 6th OBBCSSR National Conference (Promoting quality in medical laboratory activity, legislation, certification, accreditation, external quality control, continuous professional training), Bucharest, October 24th, 2010
22. **Stanciu AE**, Stanciu M, Vatasescu R, Iorgulescu C, Dorobantu M. Effects of cardiac resynchronization therapy on neurohormones and cytokines levels. 5th Conference of the Romanian Association of Medical Laboratories with International Participation, Under the auspices of IFCC and EFCC, Mamaia, June 16-19, 2010
23. **Stanciu AE**, Stafidov N, Hurdud A. Pro and antiinflammatory cytokines in differentiated thyroid carcinoma. 5th Conference of the Romanian Association of Medical Laboratories with International Participation, Under the auspices of IFCC and EFCC, Mamaia, June 16-19, 2010
24. Ionescu L, **Stanciu AE**, Trifanescu R. Inflammatory profile of Graves' disease after treatment with methimazol and before surgical intervention. 5th Conference of the Romanian Association of Medical Laboratories with International Participation, Under the auspices of IFCC and EFCC, Mamaia, June 16-19, 2010
25. **Stanciu AE**. Role of free PSA biomarker to differentiate between benign prostatic hyperplasia and prostate cancer. 5th National Conference of OBBCSSR, Bucharest, October 25, 2009
26. **Stanciu AE**, Stafidov N. News in monitoring of bladder cancer. 5th National Conference of OBBCSSR, Bucharest, October 25, 2009
27. **Stanciu AE**. The importance of BNP biomarker measurement in diagnosis, staging and monitoring of patients with heart failure. 5th National Conference of OBBCSSR, Bucharest, October 25, 2009
28. **Stanciu AE**, Dorobantu M, Vatasescu R, Iorgulescu C, Stanciu M. Biomarkers used in monitoring of patients undergoing cardiac resynchronization therapy. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology Bucharest, Poiana Brasov, September 17-19, 2009
29. **Stanciu AE**, Stafidov N, Bogdan M, Gluck G, Sinescu I, Neagoe L, Stanciu M. The level of some urinary biomarkers, urinary cytology and cystoscopy in bladder tumor recurrences. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology Bucharest, Poiana Brasov, September 17-19, 2009
30. **Stanciu AE**. Biomarkers in Chronic Heart Failure. Updates in Laboratory Medicine, Bucharest, 27 March, 2009

31. **Stanciu AE.** Some cytokines implications in patients with well differentiated thyroid cancer. Workshop "Radioisotopes & Biomolecules: A Partnership for the Early Diagnosis and Targeted Radiotherapy of Cancer", Bucharest, November 26-28, 2008
32. **Stanciu AE,** Stafidov N, Dorobantu M, Vatasescu R, Iorgulescu C, Stanciu M. The expression of biochemical markers in patients with chronic heart failure undergoing cardiac resynchronization therapy. VIASAN National Symposium - CEEEX (Module I), Sinaia, September 28-30, 2008
33. **Stanciu AE,** Stafidov N, Salageanu A, Tucureanu C, Boghean R, Dorobantu M, Vatasescu R, Iorgulescu C, Stanciu M. Biomarkers used in monitoring of patients undergoing cardiac resynchronization therapy – 38th Annual Conference of Immunology, Busteni, September 24-26, 2008
34. **Stanciu AE,** Stafidov N. Some cytokines implications in patients with thyroid cancer – 38th Annual Conference of Immunology, Busteni, September 24-26, 2008
35. **Stanciu AE,** Stafidov N, Moise G. The expression of some cytokines in thyroid cancer. National Congress of Oncology and Medical Days of Institute of Oncology Bucharest, June 20-22, 2008
36. **Stanciu AE,** Stafidov N, Dorobantu M, Vatasescu R, Stanciu M. Biomarkers in cardiac resynchronization therapy. National Congress of Oncology and Medical Days of Institute of Oncology Bucharest, June 20-22, 2008
37. **Stanciu AE.** Tumor Markers. Actualities and Perspectives. ALMR Workshop, Bucharest, March 14th, 2008
38. **Stanciu AE,** Stafidov N, Salageanu A, Tucureanu C, Boghean R. Biochemical markers used for the evaluation of cardiac resynchronisation therapy in chronic heart failure patients. National Symposium of Excellence Medical Research, Sibiu, October 25-26, 2007
39. **Stanciu AE,** Stafidov N, Stanciu M. Biomarkers used in monitoring of patients with chronic heart failure. 3rd RAML Conference with International Participation, June 27-30, 2007
40. **Stanciu AE,** Stafidov N, Bogdan M, Gluck G, Sinescu I, Stoica R, Stanciu M. Tumor markers BTA, UBC, TPS act in urinary bladder cancer. The 2nd National Conference of OBBCSSR, Bucharest, Parliament Palace, November 4-5, 2006
41. **Stanciu AE,** Stafidov N, Bogdan M, Gluck G, Sinescu I, Stoica R, Stanciu M. Tumor markers BTA, UBC, TPS, urinary cytology and cystoscopy in early recurrences of bladder tumors. National Congress of Oncology – 16th Congress of SRRO, Bucharest, October 12-14, 2006
42. Dumitru M, Nicolaescu R, **Stanciu AE,** Dancus C, Radu M, Condrea I, Vasilescu M. HER-2 expression and EGFR in cervical tumors. National Congress of Oncology – 16th Congress of SRRO, Bucharest, Oct 12-14, 2006
43. **Stanciu AE,** Stafidov N, Bogdan M, Gluck G, Sinescu I, Stoica R, Stanciu M. New biomarkers: BTA, UBC, TPS, TNF- α . National Conference of Comparative Oncology with International Participation, Tulcea, September 22-23, 2006
44. Dumitru M, Nicolaescu R, **Stanciu AE,** Dancus C, Condrea I. Her-2 expression in cervical cancer. National Conference of Comparative Oncology with International Participation, Tulcea, September 20-23, 2006
45. Gluck G, Sinescu I, Stoica R, Dragoescu O, **Stanciu AE,** Stafidov N, Bogdan M, Stanciu M. BTA, UBC, TPS tumor markers, urinary cytology and cystoscopy in bladder tumors recurrence. XXIInd Congress of the Romanian Association of Urology ROMURO 2006, Bucharest, June 24-25 2006. Abstract published in Romanian Journal of Urology, vol.5, supplement, pp.32. ISSN: 1223-0650. CNCSIS: D-486
46. **Stanciu AE,** Stafidov N, Bogdan M, Gluck G, Sinescu I, Stoica R, Dragoescu O, Stanciu M. Clinical evaluation of a few tumor markers (BTA Trak, UBC, TPS) and comparison to cytology and cystoscopy in patients with recurrent bladder tumors. 2nd Conference of the Romanian Association of Medical Laboratories with International Participation, Timișoara, May 24-27, 2006
47. **Stanciu AE,** Stafidov N, Hurduc A, Albert P, Fumarel R. Biochemical markers (TSH, ANTI-TG, TG) complementarity with scynthigraphic exam in metabolic radiotherapy of thyroid cancer. 2nd Conference of the Romanian Association of Medical Laboratories with International Participation, Timișoara, May 24-27, 2006
48. **Stanciu AE.** Tumor and hormonal markers in metabolic radiotherapy of thyroid cancer. Symposium: Update in Laboratory Medicine, Hepatology and Transplantation Immunology, Fundeni Clinical Institute, Bucharest, March 31, 2006
49. **Stanciu AE,** Stafidov N. Relation between PSA concentration and prostate cancer. The 1st National Conference of OBBCSSR, Bucharest, Parliament Palace, November 5, 2005
50. Hurduc A, Albert P, **Stanciu AE,** Stafidov N, Fumarel R. Clinical and laboratory parameters in metabolic radiotherapy. National Congress of Oncology, Bucharest, Parliament Palace, June 23-25, 2005
51. Gluck G, Costache B, Sabau V, Sinescu I, Stafidov N, **Stanciu AE.** Diagnostic performance of a few tumor markers (BTA TRAK, UBC, TPS). A comparative study with cytology and cystoscopy for evaluation of the superficial bladder tumors recurrences. National Congress of Oncology, Bucharest, Parliament Palace, June 23-25, 2005

52. **Stanciu AE**, Stafidov N. A new tumor marker: BTA. National Congress of Oncology, Bucharest, Parliament Palace, June 23-25, 2005
53. **Stanciu AE**, Stafidov N, Stanciu M. Evaluation of tumor markers expression in diagnosis and development of bladder tumors. 1st Conference of the Romanian Association of Medical Laboratories, Sibiu, June 15-18, 2005
54. **Stanciu AE**. Tumor markers in advanced forms of neoplasm monitoring. Symposium: Update in Hepatology and Laboratory Medicine, Fundeni Clinical Institute, Bucharest, April 8, 2005
55. Stanciu M, **Stanciu AE**. Optical fiber biosensor for prostate specific antigen concentration measurement. ATEE 2004, The 4th Symposium on Advanced Topics in Electrical Engineering, Bucharest, Romania (CD-ROM), ISBN: 973-7728-31-9, November 25-26, 2004
56. **Stanciu AE**, Stafidov N, Stanciu M. Prostate cancer probability determination by means of total and free PSA tumor markers. The 34th National Conference of Immunology, Bucharest, September 16-17, 2004
57. Stanciu M, **Stanciu AE**. The measurement of PSA concentration by means of sensors with optical fibers. The 3rd Conference of Clinical Laboratory Foundation "Marcela Zamfirescu Gheorghiu", Oradea, May 19-22, 2004
58. **Stanciu AE**, Stafidov N, Stanciu M. The performance of free PSA tumor marker in differentiating benign prostatic hyperplasia from prostate cancer. The 3rd Conference of Clinical Laboratory Foundation "Marcela Zamfirescu Gheorghiu", Oradea-Băile Felix, May 19-22, 2004
59. **Stanciu AE**, Stafidov N, Stanciu M. The importance of total PSA and free PSA tumoral markers in prostate cancer diagnosis. Romanian National Conference of Oncology, Bucharest, May 14-15, 2004
60. **Stanciu AE**, Stafidov N, Stanciu M. The importance of total PSA and free PSA tumoral markers in oncological treatment dynamics for patients with prostate cancer. The 2nd Conference of Clinical Laboratory Foundation "Marcela Zamfirescu Gheorghiu", Sovata, May 21-24, 2003
61. Albert P, Fumarel R, Savu M, **Stanciu AE**, Stafidov N, Hurduc A. The principles of photostimulated radio-chemotherapy with cisplatin (CDDP-PSRChT). Romanian National Conference of Oncology, Bucharest, May 9-10, 2003
62. **Stanciu AE**, Stafidov N, Stanciu M. The tumoral markers utilization in monitoring of oncological treatment. Romanian National Conference of Oncology, Bucharest, May 9-10, 2003
63. **Stanciu AE**, Stafidov N. The correlation between total PSA and free PSA in diagnosis and management of prostate cancer. The 1st Congress of Clinical Laboratory Foundation "Marcela Zamfirescu Gheorghiu", Mamaia, May 29-June 1, 2002
64. **Stanciu AE**, Stafidov N, Stanciu M. The importance of total PSA and free PSA tumoral markers in diagnosis and monitoring of prostate cancer. National Conference of Oncology, Bucharest, November 23-24, 2001
65. Fumarel R, Albert P, Hurduc A, Stafidov N, **Stanciu AE**. Scyntigraphic management of photostimulated chemotherapy. National Conference of Oncology, Bucharest, November 23-24, 2001
66. **Stanciu AE**, Stafidov N, Albert P. The PSA importance in monitoring of prostate cancer. The 1st National Congress of Nuclear Medicine with international participation, Bucharest, October 3-6, 2001
67. Albert P, Hurduc A, Stafidov N, **Stanciu AE**. Methotrexate radioactive labeling with ^{99m}Tc isotope. The 1st National Congress of Nuclear Medicine with international participation, Bucharest, October 3-6, 2001
68. Manoiu E, Gruber E, Panait M, Tache A, **Stanciu AE**, Stafidov N. The importance of immunofenotypic investigation in diagnosis and treatment of acute lymphoblastic leukemia at the children. Romanian Journal of Comparative Oncology, Annex, p. 24 - 25, 2000
69. **Stanciu AE**, Stafidov N, Manoiu E. Clinical applications of AFP and HCG tumor markers in testis cancer and choriocarcinomas. Romanian Journal of Comparative Oncology, Annex, p. 25 - 26, 2000
70. Stanciu M, **Stanciu AE**. Optical biosensor for prostate specific antigen (PSA) measurement. The 3rd Balkan Congress of Oncology, Poiana Braşov, September 10-14, 2000
71. **Stanciu AE**, Manoiu E, Stafidov N. The study of relation between ovarian cancer and breast cancer using some tumoral markers like: CA 125, HCG, CA 15 – 3. European Conference on Biomedical Research and Peace, Cyprus, October 17-21, 1999
72. **Stanciu AE**, Manoiu E, Stafidov N. The clinical applications of CA 15 – 3 and CA 125 tumoral markers in management of treatment and of cancer disease evolution at patients with breast cancer. National Conference of Oncology, Bucharest, October 14-16, 1999
73. Stanciu M, Iliescu C, Pantelimon B, **Stanciu AE**. Modeling and simulation of pH sensors with optical fibers. The 6th National Symposium of Metrology, Bucharest, September 17-18, 1997
74. **Stanciu AE**, Stanciu M. New measurement methods in oncology: optical fiber immunosensors. National Conference of Oncology, Brasov, October 21-23, 1996
75. Manoiu E, Dragomir M, **Stanciu AE**. The surface markers utilization in diagnosis of leukemia cases at the children. National Conference of Oncology, Brasov, October 21-23, 1996
76. Manoiu E, **Stanciu AE**, Stafidov N, Iosub A, Balanescu I. Clinical applications of tumor markers in the breast cancer. The International Symposium of Comparative Oncology, Tulcea – Neptun, September 24-29, 1995

77. **Stanciu AE**, Draganescu M, Manoiu E, Stafidov N. HCG, tumoral marker in testis cancer. The International Symposium of Comparative Oncology, Tulcea – Neptun, September 24-29, 1995
78. **Stanciu AE**, Draganescu M, Manoiu E, Stafidov N. The clinical signification of HCG marker in testis cancer. Annual Scientific Session of the Institute of Oncology Bucharest, May 26-27, 1995
79. Contineanu M, **Stanciu AE**. Study of paramagnetic centres formed at the radiolysis of the second group chromates, using EPR technique. 7th National Conference of Physical – Chemistry, Bucharest, 21-23.09.1994

Data: 08.09.2023

Semnatura

